Journal
SCIENTIFIC REPORTS
Volume 10, Issue 1, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/s41598-020-59368-7
Keywords
-
Categories
Funding
- Programme for Research in Third Level Institutions (PRTLI) Cycle 5
- European Regional Development Fund (ERDF), European Union Structural Funds Programme 2011-2015
- Science Foundation Ireland (SFI) under the Starting Investigator Research Grant (SIRG) Programme [15/SIRG/3482]
- PRECODE (European Union's Horizon 2020 research and innovation program under the Marie Sklodowska-Curie grant) [861196]
- EACR Travel Fellowship
- CellFit (COST Action) [CA16119]
- Science Foundation Ireland (SFI) [15/SIRG/3482] Funding Source: Science Foundation Ireland (SFI)
Ask authors/readers for more resources
With a five-year survival rate of 9%, pancreatic ductal adenocarcinoma (PDAC) is the deadliest of all cancers. The rapid mortality makes PDAC difficult to research, and inspires a resolve to create reliable, tractable cellular models for preclinical cancer research. Organoids are increasingly used to model PDAC as they maintain the differentiation status, molecular and genomic signatures of the original tumour. In this paper, we present novel methodologies and experimental approaches to develop PDAC organoids from PDX tumours, and the simultaneous development of matched primary cell lines. Moreover, we also present a method of recapitulating primary cell line cultures to organoids (CLOs). We highlight the usefulness of CLOs as PDAC organoid models, as they maintain similar transcriptomic signatures as their matched patient-derived organoids and patient derived xenografts (PDX)s. These models provide a manageable, expandable in vitro resource for downstream applications such as high throughput screening, functional genomics, and tumour microenvironment studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available